Clinical Trial Update: A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluates PDS01ADC in combination with docetaxel and abiraterone for metastatic castration-sensitive and metastatic castration-resistant pro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Castration-sensitive Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• DOCETAXEL (DOCETAXEL)
• PDS01ADC

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Cancer Of Prostate, Prostate Neoplasms | Phase 1, Phase 2 | Status: RECRUITING